clinical trial

Sarepta Announces Revised Timeline for Eteplirsen FDA Application

Boys with Duchenne muscular dystrophy between the ages of seven and 16 are now being recruited to participate in a phase 3 clinical trial to evaluate the effectiveness and safety of eteplirsen in treating DMD.

SMA: Further Data on ISIS-SMNRx Shows Promising Results

Isis Pharmaceuticals, developer of the experimental spinal muscular atrophy (SMA) drug ISIS-SMNRx, revealed positive results from phase 2 clinical studies of the drug focusing on infants and children with SMA. The new data, which was shared on October 10 by ISIS representatives attending the 19th International World Muscle Society Congress in Berlin, included the following highlights:

LEMS: Firdapse Study Shows Encouraging Results

DMD: Sarepta Updates Community on Eteplirsen, Other Compounds

MG: Multicenter Trial of Rituximab Opens

First Drug for Duchenne Muscular Dystrophy Gets 'Conditional Approval' in Europe

DMD: Ataluren Receives Conditional Approval in Europe

ISIS-SMNRx to Be Tested in Phase 3 Trial in Infants With SMA

DMD: ReveraGen Drug Will Move to Human Testing

International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug

MDA in Your Community


Grants